NEW YORK (GenomeWeb News) — Mirus Bio yesterday said it has signed a two-year, “multi-million dollar” deal with Pfizer to target and suppress the expression of certain genes.
 
Under the deal, Mirus said it will study methods for optimizing gene silencing methods in animals.
 
Mirus said the agreement will help it speed development of delivery methods for its RNAi technology.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Lawmakers have asked four direct-to-consumer genetic testing companies to explain their privacy policies and security measures, according to Stat News.

The Trump Administration has proposed a plan to reorganize the federal government, the Washington Post reports.

In Science this week: genetic overlap among many psychiatric disorders, and more.

The Economist writes that an increasing number of scientific journals don't do peer review.

Jul
19
Sponsored by
Thermo Fisher Scientific

This webinar will discuss how ultra-highly sensitive and customizable targeted next-generation sequencing panels are applied in inherited disease research.